KOD · Kodiak Sciences Inc.
$42.64
+1.39 (+3.37%)
At close · Jul 17
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our financial condition raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$2.67B
Shares
62,578,441
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | CEO | $2,725,068 |
| John Borgeson | CFO | $1,679,701 |
| Jason Ehrlich | Chief Medical Officer and Chief Development Officer | $1,399,888 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | CEO | $2,999,421 |
| Jason Ehrlich | Chief Medical Officer and Chief Development Officer | $1,625,797 |
| John Borgeson | CFO | $1,507,502 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | CEO | $113,371,207 |
| Jason Ehrlich | Chief Medical Officer and Chief Development Officer | $27,946,551 |
| John Borgeson | CFO | $27,871,802 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | CEO | $8,942,761 |
| Jason Ehrlich | Chief Medical Officer and Chief Development Officer | $3,056,247 |
| John Borgeson | CFO | $2,936,607 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | CEO | $17,642,007 |
| Jason Ehrlich | Chief Medical Officer and Chief Development Officer | $7,716,165 |
| John Borgeson | CFO | $6,223,183 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Victor Perlroth | CEO | $5,896,743 |
| Jason Ehrlich | Chief Medical Officer and Chief Development Officer | $3,745,287 |
| John Borgeson | CFO | $2,112,538 |